Ken Mills, Regenxbio CEO

Re­genxbio to seek ac­cel­er­at­ed ap­proval of Hunter syn­drome gene ther­a­py us­ing bio­mark­er da­ta

A Hunter syn­drome gene ther­a­py de­vel­oped by Re­genxbio sig­nif­i­cant­ly cut lev­els of a key bio­mark­er as­so­ci­at­ed with the dis­ease, ac­cord­ing to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.